BioCentury
ARTICLE | Clinical News

V-101: Phase II data

January 17, 2011 8:00 AM UTC

The double-blind, U.S. Phase II Study V-101-ROSE-202 trial in 183 patients with moderate to severe erythema showed that once-daily 0.1% and 0.15% V-101 for 28 days met the primary endpoint of signific...